A New Treatment Development – The Sphenoplatine Ganglion Block

Dolor Technologies has developed for the U.S. its patented, advanced drug delivery catheter, SphenoCath™. SphenoCath is a single-use, disposable catheter that delivers lidocaine via the nasal passages to a hard-to-reach ganglion (SPG) located at the back of the nose without use of painful needles, sprays, swabs or sedation, which is a real advantage. When used as prescribed, SpenoCath saturates and prolongs the medication (Lidocaine) immediately nearby to the SPG ganglion to accomplish a Sphenoplatine Ganglion or SPG block. Interventional radiologists (who recently published a paper in this subject at their annual meeting in March 2015), neurologists, internists, and pain management specialists are interested in utilizing SphenoCath for a safe, comfortable and quick delivery of the medication required for the SPG block procedure, without sedation and its myriad problems.

SphenoCath is attracting the interest of physicians who treat patients having some of the most stubborn headache disorders: cluster headaches, chronic and episodic migraine, and chronic daily headache. Hardly new in concept, SPG blocks have been studied and experimented with for many similar disorders for over a century. Lately, the SPG block has been associated with profound neuromodulation of the SPG complex, accomplishing a “resetting” the disordered signaling we associate with chronic migraine with instantaneous and long-lasting positive results.

The SPG Block is accepted as effective, however, few physicians are willing to perform an SPG block because the long-established measures they associate with it are painful for the patient and difficult for the caregiver to execute. In the past, the SPG block was executed by threading a cotton tip applicator through the nasal passages, by vaporizing a spray or with, worse still, a long needle through the side of the head. Hardly attractive approaches, and carrying no small degree of risk, medically and legally. These older approaches often require sedation and their effectiveness was sporadic. The new approach is far better, and reliable.

Now with the SphenoCath we have another option, less intrusive and painful, that may allow for relief from a number of migraine, cluster, and headache maladies in a more humane and easily achieved fashion. It is certainly worth exploring.

Comments are closed.

Font Resize